Subscribe to our Newsletters !!

    Weight Loss

    Microorganisms in the lungs could impact lung cancer progression and prognosis

    Bottom Line: Enrichment of the lungs with oral commensal microbes has been correlated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer. Journal in Which the research was Published: Cancer Discovery, a journal of the American Association for Cancer Research Author: Leopoldo Segal, MD, director of the Lung Microbiome Program,

    Scientists recognize neural circuit associated with reciprocally controlling weight gain and despondency

    Research has found that obesity and mental disorders such as depression and anxiety seem to often go together. Researchers at Baylor College of Medicine and cooperating institutions are providing new insights into this association by identifying and characterizing a novel neural circuit that mediates the reciprocal control of feeding and mental conditions in mouse models.

    Study proposes expected role for probiotics in forestalling respiratory infections

    Daily probiotic use was associated with fewer upper respiratory symptoms in overweight and older people, according to a study which suggests a potential role for probiotics in preventing respiratory infections. Researchers re-analyzed detailed daily diaries of 220 patients who engaged in a previous double-blind placebo-controlled study on probiotics and weight loss. Reviewing the entries for

    New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian disease

    Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced effective results, dramatically restricting tumor growth and diminishing tumor mass. Designed especially for ovarian cancers that are resistant to conventional therapies, the new radiopharmaceutical could be produced in 25 minutes at reduced cost, which contributes to better efficiency compared with alternative procedures. This

    Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations

    Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit